How GLP-1 medications work
The short answer
GLP-1 medications copy a hormone your gut already releases when you eat. They do four things at once: prompt insulin only when blood sugar is high, reduce the hormone that raises blood sugar, slow how fast your stomach empties, and turn down appetite signals in the brain.
That last pair is why people eat less and lose weight — and also why nausea and constipation are the most common side effects. The same mechanism drives both.
GLP-1 is a hormone you already make
Glucagon-like peptide-1 (GLP-1) is an incretin — a hormone released by cells in your intestine when food arrives. It is part of how your body coordinates digestion, insulin, and fullness after a meal.
Your natural GLP-1 is broken down within minutes by an enzyme called DPP-4. That is the central problem these drugs solve: GLP-1 receptor agonist medications are built to resist that breakdown, so instead of lasting minutes, they keep acting for days. The long-acting injectables are taken once weekly for exactly this reason.
Injection is no longer the only option
The class has changed quickly. Alongside the weekly injections, there are now daily tablets:
- Rybelsus (oral semaglutide) for type 2 diabetes, and Wegovy tablets for weight management — both must be taken on an empty stomach in the morning with no more than about four ounces of water, waiting roughly 30 minutes before eating, drinking, or taking other medication. That routine is the price of getting a peptide absorbed through the gut.
- Foundayo (orforglipron), approved in April 2026, is chemically different — a small molecule rather than a peptide. That is why it can be taken at any time of day without food or water restrictions, which is a meaningful practical difference rather than a marketing one.
If you have been searching for a “GLP-1 pill,” these are the real, FDA-approved ones. They are not the same as the unregulated supplements and “GLP-1 support” products sold online, which are a different category entirely.
The four things GLP-1 medications do
They prompt insulin — but only when blood sugar is high
GLP-1 tells the pancreas to release insulin in a glucose-dependent way: the effect switches on when blood sugar is elevated and eases off when it is not. This is why GLP-1 medications, used on their own, carry a relatively low risk of hypoglycaemia. That risk rises when they are combined with insulin or sulfonylureas, which is a conversation to have with your prescriber.
They reduce glucagon
Glucagon is insulin’s counterpart — it tells the liver to release stored glucose. GLP-1 suppresses glucagon after meals, so the liver adds less sugar to your bloodstream at the moment food is already arriving.
They slow gastric emptying
Food leaves the stomach more slowly. Two consequences follow. The helpful one: you feel full sooner and stay full longer, so you eat less without deliberately restricting. The unhelpful one: this is the direct cause of most GLP-1 side effects — nausea, early fullness, reflux, bloating, and constipation. Eating a large or fatty meal on a slowed stomach is what typically triggers the worst nausea.
They act on appetite centres in the brain
GLP-1 receptors also sit in regions of the brain that regulate hunger and reward. Acting on them reduces appetite and, for many people, quiets the persistent, intrusive thoughts about food often described as “food noise.” This is a genuine pharmacological effect, not willpower — which is also why appetite frequently returns if the medication stops.
The same slowed stomach that makes food last longer is what causes the nausea. The benefit and the side effect are not separate stories — they are one mechanism seen from two sides.
Why tirzepatide is not quite the same
Semaglutide (Ozempic, Wegovy, Rybelsus) acts on the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound) is a dual agonist: it acts on the GLP-1 receptor and also on the GIP receptor, a second incretin pathway. Both are commonly grouped under the “GLP-1” label in everyday conversation, but they are not identical drugs, and their trial results and side-effect profiles differ.
Why the dose starts low and climbs slowly
Because the gastrointestinal effects are dose-related, these medications are started at a low dose and increased in steps over weeks or months. The starting dose is generally not intended to be an effective treatment dose — it exists to let your digestive system adjust. Moving up too quickly is a common reason people find the side effects intolerable and stop. See our dosing and titration guide.
What this means in practice
- Side effects are the mechanism, not a malfunction. Feeling full quickly is the drug working; it is also why smaller, lower-fat meals help so much.
- Effects build gradually. Appetite change is often noticeable early, but these drugs reach steady levels in the body over weeks.
- It treats an ongoing condition. The appetite effect depends on the drug being present. Stopping generally means appetite returns.
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- Diabetes, obesity and digestive-disease informationNational Institute of Diabetes and Digestive and Kidney Diseases (NIH)Supports: GLP-1 as a natural incretin hormone and its role in glucose regulation.
- FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: Approved mechanism-of-action descriptions for semaglutide and tirzepatide products.
- Standards of Care in DiabetesAmerican Diabetes AssociationSupports: Clinical positioning of GLP-1 receptor agonists in diabetes care.
- StatPearls clinical referenceNCBI Bookshelf, U.S. National Library of MedicineSupports: Pharmacology background on incretin physiology and DPP-4 degradation.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.